These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19819015)

  • 1. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones.
    Sokol L; Caceres G; Rocha K; Stockero KJ; Dewald DW; List AF
    Leuk Res; 2010 Jun; 34(6):821-3. PubMed ID: 19819015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
    Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
    Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
    [No Abstract]   [Full Text] [Related]  

  • 3. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
    Geyer JT; Verma S; Mathew S; Wang YL; Racchumi J; Espinal-Witter R; Subramaniyam S; Knowles DM; Orazi A
    Hum Pathol; 2013 Mar; 44(3):346-56. PubMed ID: 22995330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.
    Schaub FX; Jäger R; Looser R; Hao-Shen H; Hermouet S; Girodon F; Tichelli A; Gisslinger H; Kralovics R; Skoda RC
    Blood; 2009 Feb; 113(9):2022-7. PubMed ID: 19047681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycythemia vera is not initiated by JAK2V617F mutation.
    Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
    Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2 V617F mutation is associated with 5q- syndrome in Chinese.
    Wong KF; Wong WS; Siu LL; Lau TC; Chan NP
    Leuk Lymphoma; 2009 Aug; 50(8):1333-5. PubMed ID: 19562618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
    Azaceta G; Calasanz MJ; Dourdil V; Bonafonte E; Izquierdo I; Palomera L
    Leuk Lymphoma; 2010 Oct; 51(10):1941-3. PubMed ID: 20846100
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.
    Giagounidis AA; Germing U; Haase S; Hildebrandt B; Schlegelberger B; Schoch C; Wilkens L; Heinsch M; Willems H; Aivado M; Aul C
    Leukemia; 2004 Jan; 18(1):113-9. PubMed ID: 14586479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic syndrome with del (5q) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with complex karyotype.
    Pich A; Godio L; Riera L; Cavaliere C; Kerim S; Bonello L; Francia di Celle P
    Ann Hematol; 2016 Feb; 95(3):525-7. PubMed ID: 26750119
    [No Abstract]   [Full Text] [Related]  

  • 12. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
    Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
    Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies.
    Veselovska J; Pospisilova D; Pekova S; Horvathova M; Solna R; Cmejlova J; Cmejla R; Belickova M; Mihal V; Stary J; Divoky V
    Leuk Res; 2008 Mar; 32(3):369-77. PubMed ID: 17719087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears.
    Bigoni R; Cuneo A; Milani R; Cavazzini F; Bardi A; Roberti MG; Agostini P; della Porta M; Specchia G; Rigolin GM; Castoldi G
    Haematologica; 2001 Apr; 86(4):375-81. PubMed ID: 11325642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
    Mesa RA; Tefferi A; Li CY; Steensma DP
    Leukemia; 2006 Nov; 20(11):2063-4. PubMed ID: 16990762
    [No Abstract]   [Full Text] [Related]  

  • 19. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
    Oka S; Ono K; Nohgawa M
    Leuk Lymphoma; 2017 Oct; 58(10):2511-2513. PubMed ID: 28278708
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.